|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-6.18/-0.99
|
企业价值
74.64M
|
资产负债 |
每股账面净值
1.45
|
现金流量 |
现金流量率
--
|
损益表 |
收益
5.00M
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/12 07:08 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |